Prospective randomized phase IV open label comparative study of dalteparin vs unfractionated heparin in high risk patients of non-ST elevation acute coronary syndromes intended for early invasive strategy.
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2011
At a glance
- Drugs Dalteparin sodium; Heparin
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 14 Oct 2011 Actual initiation date (Jun 2007) added as reported by ClinicalTrials.gov.
- 10 Mar 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.